Pluri Inc..
PLUR.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Pluri Inc., formerly Pluri Ltd., is a biotechnology company focused on cell therapy. The company develops and manufactures cell-based products for regenerative medicine and cell therapy. Pluri's technology platform, PluriMatrix, allows for the mass production of adherent cells in a three-dimensional...Show More
Better Health for All
30
Pluri Inc.'s core product, PLX-R18 cell therapy, delivers revolutionary health benefits. Preclinical studies showed significant increases in survival rates for acute radiation syndrome (from 29% to 97% and 4% to 74% in animal models).
1
Human trials demonstrated a reduction in mortality from 29% to 18% in HCT patients, and significant reductions in blood transfusions (platelets from 5.09 to 0.55 units/month, red blood cells from 2.91 to 0 units/month).
2
The company has no products with significant negative health impacts. Pluri Inc. is actively addressing global health crises by collaborating to enhance Ukraine's radiation emergency preparedness, aiming to stockpile 12,000 doses of PLX-R18.
3
This initiative also focuses on preventative health by establishing stockpiling and distribution as a countermeasure against H-ARS, targeting a vulnerable population in Ukraine.
4
The company received a $4.2 million, three-year contract from the U.S. National Institutes of Health (NIH) to advance PLX-R18 development, indicating significant health innovation investment.
5
The FDA has granted Orphan Drug Designation for PLX-R18, and an Investigational New Drug (IND) application has been cleared, with clinical trials being a goal of the collaboration in Ukraine.
6
Fair Money & Economic Opportunity
0
Pluri Inc. is a biotechnology company focused on cell therapy, research, and development. Its core business activities, as evidenced by the provided articles, revolve around biotech collaborations, financial strategy, investments, acquisitions, and product development in the biotech and food-tech sectors. The company does not operate in the financial services industry, nor does it offer lending, deposit services, or any financial products to consumers. Consequently, none of the Key Performance Indicators (KPIs) for the 'Fair Money & Economic Opportunity' value are applicable to its business model, and no relevant evidence was found in the provided articles to score any of these KPIs.
Fair Pay & Worker Respect
40
Pluri Inc. received the 2022 Egalitarian Employment Award in the Large Company category from Israel's Ministry of Labor, Social Affairs and Social Services, marking the second time the company has won this award.
1
The company has a robust compensation policy in place to ensure gender pay equity.
2
Female employees represent an equal part of Pluri's total workforce, including senior management and executive level positions.
3
Fair Trade & Ethical Sourcing
0
No specific, concrete evidence was found in the provided articles for any of the KPIs related to Fair Trade & Ethical Sourcing. The articles discuss general company information, internal employee diversity and awards, and general importance of supply chain sustainability, but do not provide data on fair trade certifications, audit frequency, forced/child labor incidents, supply chain traceability, remediation speed, ethical clause coverage in supplier contracts, materials risk index, or supplier diversity spend for Pluri Inc.
1
Honest & Fair Business
0
No evidence available to assess Pluri Inc. on Honest & Fair Business.
Kind to Animals
0
Pluri's technology platform aims to advance novel cell-based solutions for challenges including animal cruelty.
1
The company's majority-owned subsidiary, Ever After Foods, a joint venture with Tnuva Group, is using PluriMatrix to produce cultivated meat, aiming to become a global leader in cultivated food.
2
Pluri has a joint venture with Tnuva Group to establish a cultured food platform and establishes partnerships leveraging its proprietary 3D cell-based technology across various industries that require effective, mass cell production.
3
No War, No Weapons
-20
Pluri Inc. has a $4.2 million contract with the U.S. National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), for the development of PLX-R18.
1
This project involves collaboration with the U.S. Department of Defense’s Armed Forces Radiobiology Research Institute (AFRRI)/Uniformed Services University of Health Sciences (USUHS).
2
PLX-R18 is a medical countermeasure for Hematopoietic Acute Radiation Syndrome (H-ARS), which is relevant for both civilian nuclear accidents and military/terrorist scenarios, making it a dual-use technology intended for the U.S. Strategic National Stockpile.
3
The company's Code of Business Conduct and Ethics establishes ethical red lines related to conflicts of interest, public reporting, anti-corruption, quality, fair dealing, competition, insider trading, and property use.
4
The Board of Directors is responsible for approving waivers and amendments to this Code for directors and executive officers, and the CFO reports to the Board on material issues related to the Code, with the Board evaluating alleged violations and determining disciplinary measures.
5
Planet-Friendly Business
0
No evidence available to assess Pluri Inc. on Planet-Friendly Business.
Respect for Cultures & Communities
0
No evidence available to assess Pluri Inc. on Respect for Cultures & Communities.
Safe & Smart Tech
-40
Pluri Inc. engages in periodic assessment and testing of cybersecurity policies, including vulnerability testing, and regularly engages third parties for assessments.
1
Critical vulnerabilities are patched within 21-30 days on average, which aligns with good vulnerability management practices. The company states it intends to put in place additional mechanisms to ensure compliance with GDPR, indicating current compliance may have gaps, and mentions that failure to comply with privacy regulations is a potential risk factor.
2
The company also states that 40-55% of its systems undergo regular security testing, with a comprehensive methodology for critical systems. Privacy considerations are integrated into the development process, but the extent of privacy impact assessments is not specified, suggesting a standard approach.
Zero Waste & Sustainable Products
-40
Pluri Inc. has implemented several waste reduction initiatives, including a comprehensive recycling program for batteries, paper, power, and plastic.
1
The company also uses reusable parts in its cell manufacturing systems, donates old equipment, and is switching plastic products to pure bioplastics.
2
These efforts have resulted in $100,000 in reclaimed costs from materials originally intended for destruction.
3
The company has a specific waste reduction target to offer all plastic products made exclusively from bioplastics by 2027.
4
For customer waste education, most customer communication and orders are handled digitally, and the company supports Pluristyle, a clothing re-sale charity benefit.
5